



## Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study

Manuela Casula<sup>a,b,\*</sup>, Marta Gazzotti<sup>c</sup>, Maria Elena Capra<sup>d</sup>, Elena Olmastroni<sup>a,b</sup>, Federica Galimberti<sup>b</sup>, Alberico L. Catapano<sup>b</sup>, Cristina Pederiva<sup>e</sup>, the LIPIGEN Group and the LIPIGEN Paediatric Group

<sup>a</sup> Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, 20133, Italy

<sup>b</sup> IRCCS MultiMedica, Sesto San Giovanni, Milan, 20099, Italy

<sup>c</sup> Fondazione SISA (Società Italiana per lo Studio dell'Aterosclerosi), 20133, Milano, Italy

<sup>d</sup> Centre for Paediatric Dyslipidaemias, Paediatrics and Neonatology Unit, Guglielmo da Saliceto Hospital, 29121, Piacenza, Italy

<sup>e</sup> Clinical Service for Dyslipidaemias, Study and Prevention of Atherosclerosis in Childhood, Paediatrics Unit, ASST-Santi Paolo e Carlo, 20142, Milan, Italy

### ARTICLE INFO

#### Keywords:

Paediatric familial hypercholesterolemia  
Genetic dyslipidemia  
Childhood  
Pathology registry

### ABSTRACT

**Background and aims:** We aimed to describe the limitations of familial hypercholesterolemia (FH) diagnosis in childhood based on the presence of the typical features of FH, such as physical signs of cholesterol accumulation and personal or family history of premature cardiovascular disease or hypercholesterolemia, comparing their prevalence in the adult and paediatric FH population, and to illustrate how additional information can lead to a more effective diagnosis of FH at a younger age.

**Methods:** From the Italian LIPIGEN cohort, we selected 1188 ( $\geq 18$  years) and 708 ( $< 18$  years) genetically-confirmed heterozygous FH, with no missing personal FH features. The prevalence of personal and familial FH features was compared between the two groups. For a sub-group of the paediatric cohort ( $N = 374$ ), data about premature coronary heart disease (CHD) in second-degree family members were also included in the evaluation.

**Results:** The lower prevalence of typical FH features in children/adolescents vs adults was confirmed: the prevalence of tendon xanthoma was 2.1% vs 13.1%, and arcus cornealis was present in 1.6% vs 11.2% of the cohorts, respectively. No children presented clinical history of premature CHD or cerebral/peripheral vascular disease compared to 8.8% and 5.6% of adults, respectively. The prevalence of premature CHD in first-degree relatives was significantly higher in adults compared to children/adolescents (38.9% vs 19.7%). In the sub-cohort analysis, a premature CHD event in parents was reported in 63 out of 374 subjects (16.8%), but the percentage increased to 54.0% extending the evaluation also to second-degree relatives.

**Conclusions:** In children, the typical FH features are clearly less informative than in adults. A more thorough data collection, adding information about second-degree relatives, could improve the diagnosis of FH at younger age.

### 1. Introduction

Familial hypercholesterolaemia (FH) is the most common inherited metabolic disease with an autosomal dominant mode of inheritance, characterized by high levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) since birth, leading to premature coronary artery disease (CAD) [1].

Owing to a genetic defect mainly in the low-density lipoprotein (LDL)-receptor (LDLR) pathway, affected patients cannot clear LDL particles from the circulation, causing a life-long accumulation of low-density lipoprotein cholesterol (LDL-C) in plasma and a consequent accelerated atherosclerosis process, if untreated [2].

Although the high cardiovascular risk associated with the disease makes early diagnosis and initiation of treatment of outmost

\* Corresponding author. Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133, Milan, Italy.

E-mail address: [manuela.casula@unimi.it](mailto:manuela.casula@unimi.it) (M. Casula).

<https://doi.org/10.1016/j.atherosclerosis.2023.117231>

Received 16 March 2023; Received in revised form 26 July 2023; Accepted 8 August 2023

Available online 12 August 2023

0021-9150/© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

importance, identifying individuals with FH at a younger age poses several challenges [3,4]. In most international contexts, as in Italy, there is no systematic paediatric screening, and the diagnosis of FH in children and adolescents is mostly by chance or after cascade screening following the identification of an affected person in the family. Moreover, it is often entrusted to non-specialised physicians, mostly paediatricians, with fragmentary or limited knowledge about FH.

The utilisation of algorithms supporting the clinical diagnosis, such as the Dutch Lipid Clinic Network (DLCN) score [5] recommended by European guidelines [6] or Simon Broome (SB) criteria [7], is of limited applicability in children [8,9]. These tools are essentially based on clinical features of the disease in adulthood, which are often absent in subjects under 18 years: high LDL-C levels and their consequences, i.e. physical signs of lipid accumulation (xanthomas, xanthelasmas, and juvenile corneal arch) and the onset of premature cardiovascular events (before 55 years in men and before 60 years in women), as well as a family history of hypercholesterolaemia and early cardiovascular events [4,10–12]. Indeed, with the exception of the most severe cases of FH in homozygous form, LDL-C levels in FH children and adolescents are often not as high as in adults, and could be influenced by puberty [13,14]. In addition, the cumulative cholesterol burden is usually not sufficient to result in the development of physical signs or early events. Finally, the young age of the children often coincides with the young age of the parents, who often do not have (yet) developed a cardiovascular event despite the presence of FH, also thanks to treatment with lipid lowering medications [4,15]. Moreover, as also reported in adult age [16], the applicability of the diagnostic algorithms can be limited by the difficulties to retrieve all crucial parameters/information, such as diseases and health conditions in the family.

These limitations call for further research in the population of young patients with FH. A valuable support is offered by disease registries, which collect relevant clinical, biochemical, and genetic information [17]. In Italy, the LIPIGEN register has been active since 2016, thanks to the collaboration of more than 50 lipid clinics throughout the country [18], committed to collecting data on patients with a clinical or genetic diagnosis of FH. Within the main project, the LIPIGEN Paediatric Group was created in 2018 [13]. One of the aims of this initiative was to refine data collection in the sub-population of young FH patients, in order to provide the basis for an improved diagnostic and therapeutic approach.

The aim of the present analysis was to describe the limitations of relying on the presence of typical features of FH for a diagnosis in paediatric subjects, and to illustrate how the integration of data collection with additional information can support the diagnosis of FH at a younger age.

## 2. Patients and methods

### 2.1. Study population and data source

The LIPIGEN-FH study is an observational, multicentre, retrospective and prospective study [18]. The study has been approved by the Institutional Review Board of each participating center and conducted in accordance with the principles of the Helsinki Declaration, the standards of Good Clinical Practice (ICH GCP), the data protection laws, and other applicable regulations. Patients of any age and sex, with clinical suspicion of FH, who are able to understand the study procedures and who voluntarily agree to participate by providing written informed consent, may be included in the study. Detailed information about the procedures of LIPIGEN study has been previously published [18].

We restricted our analysis to adults ( $\geq 18$  years) and children/adolescents ( $< 18$  years), with genetic diagnosis of heterozygous FH (i.e., with one causative variants in one of the FH-causing candidate genes [19]), without missing values in personal criteria [5] such as data about physical examination and personal clinical history, and with known untreated LDL-C levels.

### 2.2. Patient characteristics

For each subject, anamnestic, anthropometric, biochemical and genetic data were collected.

The prevalence of several FH features was evaluated for both cohorts. Typical clinical manifestations of FH included (in addition to LDL-C) personal clinical history of tendon xanthoma or arcus cornealis at age before 45 years at physical examination, development of a premature coronary heart disease and/or premature cerebral or peripheral vascular disease in the subjects (before 55 years in males and before 60 years in females). Data about family history considered the presence of first-degree relative with known premature coronary heart disease (CHD), with hypercholesterolemia (LDL-C  $> 190$  mg/dL), and/or with tendon xanthoma/cornealis arcus at age  $< 45$ .

The work of the LIPIGEN Paediatric Group led to the integration of the electronic Case Report Form (eCRF), initially designed only for adult patients, with additional information specifically for children and adolescents. Based on the observation that children with FH have parents who are often young and already under lipid-lowering treatment, two factors that reduce the likelihood of a premature cardiovascular event, the family cardiovascular history evaluation was extended to grandparents.

**Table 1**

Prevalence of typical features of FH in adults (N = 1188) and in subjects under 18 years (N = 708).

	Adults	Subjects $< 18$ y	p
<b>Females, %</b>	52.8	50.6	0.37
<b>Age in years, mean SD</b>	40.7 $\pm$ 14.6	10.3 $\pm$ 4.2	
<b>Untreated LDL-C (mg/dL), mean SD</b>	269.1 $\pm$ 71.3	227.5 $\pm$ 50.4	$< 0.0001$
LDL-C $> 155$ mg/dL, %	98.1	94.2	$< 0.0001$
LDL-C $> 190$ mg/dL, %	91.8	76.4	$< 0.0001$
LDL-C $> 250$ mg/dL, %	55.7	28.4	$< 0.0001$
<b>Physical examination, %</b>			
Tendon xanthoma	13.1	2.1	$< 0.0001$
Arcus cornealis at age $< 45$	11.2	1.6	$< 0.0001$
<b>Clinical history, %</b>			
Clinical history of premature CHD	8.8	0.0	$< 0.0001$
Clinical history of premature cerebral or peripheral vascular disease	5.6	0.0	$< 0.0001$
<b>Family history, %</b>			
First-degree relative with known premature CHD	38.9	19.7	$< 0.0001$
First-degree relative with known LDL-C $> 190$ mg/dL	92.9	93.5	0.63
First-degree relative with tendon xanthoma and/or corneal arcus at age $< 45$	18.7	20.0	0.52

LDL-C LDL-cholesterol; CHD coronary heart disease.

### 2.3. Statistical analysis

Continuous variables are expressed as mean and standard deviation (SD) while categorical data as absolute frequencies and percentages. Continuous variables were compared using *t*-test, while categorical variables were compared by chi-square or Fisher's exact tests.

Data analysis was performed using SAS (Statistical Analysis System) software version 9.4 (SAS. Institute, Inc. Cary, North Carolina), and two-tailed  $p < 0.05$  was considered for statistical significance in all analyses.

### 3. Results

A total of 1896 genetically confirmed heterozygous FH subjects (N = 1188 adults [52.8% females], and N = 708 children/adolescents [50.6% females]) were included in the analysis (Table 1), with a mean age of  $40.7 \pm 14.6$  years and  $10.3 \pm 4.2$  years, respectively. The prevalence of the typical features of FH was lower in children/adolescents compared to adults: tendon xanthoma was identified in 13.1% of adult vs 2.1% of children/adolescent patients ( $p < 0.0001$ ), a similar difference was detected also for the arcus cornealis (11.2% vs 1.6%,  $p < 0.0001$ , respectively). No children presented a clinical history of premature CHD or cerebral/peripheral vascular disease, identified in 8.8% and 5.6% of the adults, respectively.

The prevalence of first-degree relatives with tendon xanthoma and/or corneal arcus was comparable among adults and children (18.7% and 20.0%, respectively;  $p = 0.52$ ), as well as the presence of hypercholesterolemia in first-degree family members (92.9% vs 93.5%, respectively;  $p = 0.63$ ). A premature CHD in first-degree relatives was reported in 38.9% of adult FH, and only in 19.7% of subjects under 18 years ( $p < 0.0001$ ). Adults also presented significantly higher level of untreated LDL-C compared to the paediatric cohort:  $269.1 \pm 71.3$  mg/dL vs  $227.5 \pm 50.4$  ( $p < 0.0001$ ; Fig. 1); in addition, the percentage of subjects with LDL-C values above 250 mg/dL in adults was two times higher than children/adolescents (55.7% vs 28.4%,  $p < 0.0001$ ).

The analysis on additional data collection in the paediatric population about premature event also in second-degree relatives was carried out on a subgroup of 374 children/adolescents for whom this information was available. This sub-cohort was representative of the whole paediatric cohort, as no significant differences in sex, age at baseline, untreated LDL-C levels, and clinical manifestation of FH were observed (data not shown).

A premature cardiovascular event in the parents was reported in 16.8% of the paediatric sub-group, but the percentage increased to 54.0% extending the evaluation also in second-degree family members




Fig. 1. Distribution of LDL-cholesterol (mg/dL) among adults and subjects <18 years.

(Fig. 2). In details, 136 subjects presented a premature CHD at least in one grand-parent and 19 subjects at least in one parent and/or one grand-parent. Within the paediatric sub-group with LDL-C >190 mg/dL (74.1%), the prevalence increased from 14.8% to 54.2%.

### 4. Discussion

Our analysis clearly illustrated that the criteria routinely used for the clinical diagnosis of FH in adults are less effective at detecting paediatric patients. The comparison between the phenotype of LIPIGEN adults and children allowed to identify a significant higher prevalence of typical features of FH in adults which were less frequent in children. This difference can be explained by their young age and temporal limited exposure to high levels of LDL-C (less cumulative cholesterol burden) leading to the lack of typical signs of FH, as reported also in a Portuguese FH cohort, where out of 295 children (mean age 10 years old) none presented with CHD or tendon xanthoma [20].

The first obvious adjustment for a better clinical decision making relates to the cut-offs for LDL-C. However, this cannot simply be solved by reducing the thresholds, as fluctuations in cholesterol concentrations with age are present [13], and the approach should be age-specific. As such, a diagnostic approach based primarily on LDL-C would lead to the identification of only the most severe cases, with very high levels, and would be poorly sensitive. Therefore, the evaluation of the family history becomes relevant, even more so in the younger population.

In our analysis, we investigated whether additional parameters can improve the FH diagnosis in children [21], by further leveraging on family history. Our data show a significant difference in the prevalence of first-degree relatives with known premature CHD, only in 21% of children compared to 39% of adults. Notably, once we extended the family history information to second-degree family members in the paediatric sub-cohort, the prevalence of premature CHD in first- and second-degree relatives increased to more than 54% (Fig. 3). A similar trend was also observed in the Dutch registry where a history of CHD was reported in 20% of FH parents (mean age 41 years old) and in 49% of grand-parents (mean age 51 years) [22].

These observations support the proposal of refinements of the diagnostic approach with a tailored data collection at younger age and emphasises the importance of assessing, in all children visiting a doctor (whatever the reason), the family history regarding cholesterol levels, cardiovascular disease and confirmed or suspected genetic conditions not only in parents, but also extending the evaluation at least at second-degree family members.

In a disease such as FH, early diagnosis remains a central point to control for the exceedingly high risk of this population, if untreated. Many screening approaches have been proposed, targeting different age groups, and none has proved better than the others [23]. The simple lipid test, combined with an accurate family history evaluation, may be a viable and low-cost option.

On the other hand, it should be noted that the main limitation of this approach is related to the difficulties in collecting family data. In particular cases, such as adoptions, complex family situations, or others, to reconstruct family data is challenging [4]. The inclusion criteria for this analysis were established to reduce the relevant impact of missing data on the performance of diagnostic algorithms, as previously demonstrated [16]. However, an evaluation on the whole LIPIGEN cohort showed that information about family history resulted to be difficult to be gather in both age groups (in the overall LIPIGEN cohort, proportions of missing data about premature CHD in first-degree family members: 4.7% in adults and 4.9% in children/adolescents; proportions of missing data about presence of LDL-C >190 mg/dL in first-degree family members: 7.8% in adults and 10.2% in children/adolescents; data not shown). To improve FH detection and to fill in this gap, general practitioners and family paediatricians should be aware of the importance of collecting a CHD-oriented family history. Moreover, any medical doctor who takes care of adult or paediatric subjects should




Fig. 2. Prevalence of premature cardiovascular (CV) events in parents/grandparents reported in the whole paediatric subgroup and in children/adolescent with LDL-cholesterol >190 mg/dL.




Fig. 3. Graphical abstract.

periodically update CHD-oriented family history data.

The high number of paediatric patients in the LIPIGEN register is one of the main strengths of our network, as well as the presence in the same national register of both adult and paediatric populations. However, our results should be interpreted considering potential limitations. One criticism relates to the absence of control cohorts of non-FH patients, which will be crucial for future evaluation of the specificity of an adapted diagnostic algorithm [24]. On the other hand, in order to have robust results, we limited our cohort to subjects with genetic diagnosis of FH. However, it was shown that, in a considerable proportion of subjects with a FH phenotype, no pathogenic variant is found [25]. Genetically negative subjects show mostly a milder phenotype [26], and in these subjects the described limitations for early diagnosis would be even

more impactful.

In conclusion, the analysis of data extracted from the LIPIGEN registry highlighted few challenges in FH diagnosis, especially for paediatric patients. Clearly, FH diagnosis based on signs of the disease and on the clinical consequences of medium-to long-term exposure to high LDL-C levels is not efficient in young patients. Our evidence should discourage the stringent use of diagnostic algorithms in this population. On the other hand, the hallmark of the disease is primarily the elevated lipid levels. This implies the need to measure these levels in the paediatric population. This assessment would provide the starting point for a diagnostic suspicion, which can be supported by family investigation, extended to second-degree relatives when the information is available. Health decision-makers could consider targeted paediatric screening,



perhaps by integrating cholesterol measurement with the administration of childhood vaccines, or by providing free screening in primary schools. Another strategy that needs to be enhanced is the cascade screening, i.e. screening in the children of adults affected by FH. Finally, it is important to highlight that once a child is diagnosed with FH as index case in a family, this should lead to screening in all family members (the so-called reverse cascade screening). We believe that active collaboration among medical doctors dealing with adult subjects and with paediatric ones, together with institutions' and patients associations' involvement, will help spread FH knowledge and awareness, and increase the number of patients diagnosed with FH since childhood [27].

### Financial support

The authors received no financial support for the research, authorship, and/or publication of this article.

The LIPIGEN study is an initiative of the SISA Foundation supported by an unconditional research grants from Amgen and Sanofi.

### Data availability statement

The data that support the findings of this study are available from the corresponding author (MC) upon reasonable request.

### CRedit authorship contribution statement

**Manuela Casula:** Investigation, Data curation, Writing – original draft. **Marta Gazzotti:** Investigation, Data curation, Writing – original draft. **Maria Elena Capra:** Conceptualization, Methodology, Writing – review & editing. **Elena Olmastroni:** Formal analysis. **Federica Galimberti:** Writing – original draft. **Alberico L. Catapano:** Conceptualization, Supervision, Writing – review & editing. **Cristina Pederiva:** Conceptualization, Methodology, Writing – review & editing.

### Declaration of competing interest

All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. MG, MC, MEC, EO, FG, and CP report no conflict of interest disclosures. ALC received research funding and/or honoraria for advisory boards, consultancy or speaker bureau from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Mediolanum, Merck or MSD, Pfizer, Recordati, Rottapharm, Sanofi-Regeneron, Sigma-Tau.

### Acknowledgements

The genetic assessment was performed in collaboration with GenInCode, Barcelona, Spain.

The work of MC has been supported by Italian Ministry of Health-IRCCS MultiMedica GR-2016-02361198.

The work of ALC has been supported by Italian Ministry of Health-IRCCS MultiMedica RF-2019-12370896, SISA Lombardia, and Fondazione SISA.

The work of ALC, MC, and FG has been also supported by Italian Ministry of Health - Ricerca Corrente - IRCCS MultiMedica.

### Appendix. Members of LIPIGEN Group and LIPIGEN Paediatric Group

Adriano **Anesi** (UOM Laboratorio Patologia Clinica, Dipartimento Laboratori, APSS, Trento, Italy), Marcello **Arca** (Department of Translational and Precision Medicine, Sapienza University of Rome, Italy), Renata **Auricchio** (Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli Federico II, Naples, Italy), Maurizio **Averna** (Department of Health Promotion, Mother and Child Care,

Internal Medicine and Medical Specialties [PROMISE], Università degli Studi di Palermo, Palermo, Italy; Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy), Davide **Baldera** (Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari, Cagliari, Italy), Giuseppe **Banderali** (U.O. Clinica Pediatrica, Servizio Clinico Dislipidemie per lo Studio e la Prevenzione dell'Aterosclerosi in età Pediatrica, ASST-Santi Paolo e Carlo, Milan, Italy), Guglielmo **Beccuti** (SCDU Endocrinologia, Diabetologia e Malattie del Metabolismo, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Turin, Italy), Andrea **Benso** (SCDU Endocrinologia, Diabetologia e Malattie del Metabolismo, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Turin, Italy), Martina **Berteotti** (Dipartimento medicina sperimentale e clinica, Università di Firenze, AOU Careggi, Firenze, Italy), Stefano **Bertolini** (Department of Internal Medicine, University of Genoa, Genoa, Italy), Vanessa **Bianconi** (Sez. Medicina Interna, Angiologia e Malattie da Arteriosclerosi, Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia, Perugia, Italy), Giacomo **Biasucci** (Università di Parma, Centro Dislipidemie in Età Evolutiva, U.O. Pediatria e Neonatologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy), Gianni **Biolo** (S.S. Malattie del Metabolismo, U.C. O. Clinica Medica, ASUGI, Università di Trieste, Trieste, Italy), Luca **Bonanni** (Ambulatorio Dislipidemie, UO Medicina Interna, Ospedale dell'Angelo di Mestre, Venice, Italy), Claudio **Borghi** (U.O. di Medicina Interna Cardiovascolare, Ambulatorio Dislipidemie, Università di Bologna, IRCCS S.Orsola, Bologna, Italy), Antonio Carlo **Bossi** (U.O.C. Malattie Endocrine e Centro Regionale per il Diabete Mellito, ASST Bergamo Ovest, Treviglio, Bergamo, Italy), Adriana **Branchi** (Ambulatorio Dislipidemie, Centro per lo Studio e la Prevenzione dell'Arteriosclerosi, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy), Patrizia **Bruzzi** (U.O.C. Pediatria, Azienda Ospedaliero Universitaria di Modena, Modena, Italy), Marco **Bucci** (Clinica Medica, Centro di alta specializzazione per la prevenzione dell'Aterosclerosi, centro di eccellenza ESH per l'ipertensione arteriosa, centro di riferimento regionale per le Dislipidemie, Ospedale Policlinico S.S. Annunziata, Chieti, Italy), Paola Sabrina **Buonuomo** (Rare Diseases and Medical Genetic Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy), Paolo **Calabrò** (U.O.C. Cardiologia Clinica a Direzione Universitaria e U.T.I.C., A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy; Dipartimento di Scienze Mediche Traslazionali Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy), Sebastiano **Calandra** (Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy), Francesca **Carubbi** (U.O. Medicina interna metabolica, Lipigen Center, Baggiovara Hospital, AOU of Modena, Modena, Italy; University of Modena and Reggio Emilia, Modena, Italy), Raimondo **Cavallaro** (UOC Medicina Interna 2, Centro per le malattie da aterosclerosi, AORN Cardarelli, Naples, Italy), Angelo Baldassarre **Cefalù** (Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties [PROMISE], Università degli Studi di Palermo, Palermo, Italy), Arturo **Cesaro** (U.O.C. Cardiologia Clinica a Direzione Universitaria e U.T.I.C., A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy; Dipartimento di Scienze Mediche Traslazionali Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy), Francesco **Cipollone** (Clinica Medica, Centro di alta specializzazione per la prevenzione dell'Aterosclerosi, centro di eccellenza ESH per l'ipertensione arteriosa, centro di riferimento regionale per le Dislipidemie, Ospedale Policlinico S.S. Annunziata, Chieti, Italy), Nadia **Citroni** (Centro Dislipidemie e Aterosclerosi, UOC Medicina Interna, Ospedale di Trento, APSS, Trento, Italy), Emanuela **Colombo** (ASST-Rhodense Garbagnate Milanese, Garbagnate Milanese, Milan, Italy), Chiara **Coppola** (U.O. di Medicina Interna e Geriatria "C. Frugoni" e Centro di Assistenza e Ricerca Malattie Rare, A.O. Universitaria Policlinico Consorziale, Università degli Studi di Bari "Aldo Moro", Bari, Italy), Sergio **D'Addato** (U.O. di Medicina Interna Cardiovascolare, Ambulatorio Dislipidemie, Università di Bologna, IRCCS S.Orsola, Bologna, Italy), Beatrice **Dal Pino**

(Lipoapheresis Unit - Reference Center For Diagnosis And Treatment Of Inherited Dyslipidemias - Fondazione Toscana Gabriele Monasterio - Pisa, Italy), Edoardo **Dalla Nora** (Center for the Study and Treatment of Metabolic Diseases, Atherosclerosis, and Clinical Nutrition, University Hospital of Ferrara Arcispedale Sant'Anna, Ferrara, Italy), Giuseppe **De Corrado** (SC Malattie Metaboliche e Diabetologia, Ospedale Cardinal Massaia, ASL AT, Asti, Italy), Maria **Del Ben** (Dipartimento Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari - Sapienza Università, A.O. Policlinico Umberto I, Rome, Italy), Sergio **Di Molfetta** (Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy), Maria Donata **Di Taranto** (Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli studi di Napoli Federico II and CEINGE Biotecnologie Avanzate Franco Salvatore, Naples, Italy), Giulia **Fainelli** (Servizio di Diabetologia e Malattie Metaboliche "Ospedale P. Pederzoli" - Casa di Cura Privata S.p.A., Peschiera del Garda, Italy), Massimo **Federici** (Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma, Tor Vergata, Rome, Italy), Claudio **Ferri** (Università dell'Aquila - Dipartimento MeSVA - UOC Medicina Interna e Nefrologia - Centro Ipertensione Arteriosa e Prevenzione Cardiovascolare - Ospedale San Salvatore - L'Aquila, Italy), Anna Maria **Fiorenza** (ASST-Rhodense Garbagnate Milanese, Garbagnate Milanese, Milan, Italy), Elena **Formisano** (IRCCS Ospedale policlinico San Martino UOSD Dietetica e Nutrizione Clinica, Dipartimento di Medicina Interna, Università di Genova, Genoa, Italy), Giuliana **Fortunato** (Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli studi di Napoli Federico II and CEINGE Biotecnologie Avanzate Franco Salvatore, Naples, Italy), Andrea **Giaccari** (Università Cattolica del Sacro Cuore, Rome, Italy; Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy), Francesco **Giorgino** (Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy), Liliana **Grigore** (IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy), Ornella **Guardamagna** (Paediatric Endocrinology, Department of Public Health and Paediatric Sciences, Turin University, Turin, Italy), Arcangelo **Iannuzzi** (UOC Medicina Interna 2, Centro per le malattie da aterosclerosi, AORN Cardarelli, Naples, Italy), Gabriella **Iannuzzo** (Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy), Lorenzo **Iughetti** (U.O.C. Pediatria, Azienda Ospedaliero Universitaria di Modena, Modena, Italy), Salvatore **Lia** (AOU San Luigi Gonzaga, Orbassano, Turin, Italy), Susanna **Longo** (Dipartimento di Medicina dei Sistemi, Università degli Studi di Roma, Tor Vergata, Rome, Italy), Alessandro **Lupi** (ASL VCO - SOC Cardiologia, Ospedale Castelli, Verbania, Italy), Giuseppe **Mandraffino** (Department of Clinical and Experimental Medicine - Lipid Center - University Hospital G. Martino, Messina, Italy), Rossella **Marcucci** (Dipartimento medicina sperimentale e clinica, Università di Firenze, AOU Careggi, Firenze, Italy), Lorenzo **Maroni** (Ambulato Dislipidemie, U.O. Cardiologia Riabilitativa, Medicina Generale, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy), Giulia **Massini** (Paediatric Endocrinology, Department of Public Health and Paediatric Sciences, Turin University, Turin, Italy), Elisa **Mazza** (Dipartimento Scienze Mediche Chirurg., Università degli Studi Magna Graecia, Catanzaro, Italy), Elena **Melchioda** (AOU San Luigi Gonzaga, Orbassano, Turin, Italy), Giancarla **Meregalli** (U.O.C. Malattie Endocrine e Centro Regionale per il Diabete Mellito, ASST Bergamo Ovest, Treviglio, Bergamo, Italy), Ilenia **Minicocci** (Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università di Roma, Rome, Italy), Simona **Moffa** (Università Cattolica del Sacro Cuore, Rome, Italy; Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy), Giuliana **Mombelli** (Centro Dislipidemie, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy), Sandro **Muntoni** (Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari, Cagliari, Italy; Centro per le Malattie Dismetaboliche e l'Arteriosclerosi, Associazione

ME.DI.CO. Onlus Cagliari, Cagliari, Italy), Fabio **Nascimbeni** (U.O. Medicina interna metabolica, Lipigen Center, Baggiovara Hospital, AOU of Modena, Modena, Italy), Emanuele Alberto **Negri** (Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy), Serena **Notargiacomo** (Università dell'Aquila - Dipartimento MeSVA - UOC Medicina Interna e Nefrologia - Centro Ipertensione Arteriosa e Prevenzione Cardiovascolare - Ospedale San Salvatore - L'Aquila, Italy), Filippo Maria **Panfilì** (Rare Diseases and Medical Genetic Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy), Gianfranco **Parati** (Istituto Auxologico Italiano, IRCCS, San Luca Hospital, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy), Angelina **Passaro** (Department of Translational Medicine, University of Ferrara, Ferrara, Italy; Center for the Study and Treatment of Metabolic Diseases, Atherosclerosis, and Clinical Nutrition, University Hospital of Ferrara Arcispedale Sant'Anna, Ferrara, Italy), Chiara **Pavanello** (Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy; Centro Dislipidemie ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy), Valerio **Pecchioli** (UOSD 'Prevenzione cardiovascolare', Dipartimento di Scienze Mediche, Azienda Sanitaria Locale Frosinone, Frosinone, Italy), Lorenzo **Pecchioli** (UOSD 'Prevenzione cardiovascolare', Dipartimento di Scienze Mediche, Azienda Sanitaria Locale Frosinone, Frosinone, Italy), Fabio **Pellegatta** (IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy), Francesco Massimo **Perla** (Dipartimento Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari - Sapienza Università, A.O. Policlinico Umberto I, Rome, Italy), Antonio **Pipolo** (AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy), Salvatore **Piro** (Department of Clinical and Experimental Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy), Matteo **Pirro** (Sez. Medicina Interna, Angiologia e Malattie da Arteriosclerosi, Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia, Perugia, Italy), Livia **Pisciotta** (IRCCS Ospedale policlinico San Martino UOSD Dietetica e Nutrizione Clinica, Dipartimento di Medicina Interna, Università di Genova, Genoa, Italy), Roberta **Pujia** (Dipartimento Scienze Mediche Chirurg., Università degli Studi Magna Graecia, Catanzaro, Italy), Carolina **Putotto** (Dipartimento Materni Infantile e Scienze Urologiche - Sapienza Università di Roma, Rome, Italy), Elena **Repetti** (SC Malattie Metaboliche e Diabetologia, Ospedale Cardinal Massaia, ASL AT, Asti, Italy), Elisabetta **Rinaldi** (U.O. Endocrinologia, Diabetologia e Malattie del Metabolismo, Centro regionale specializzato per la diagnosi e terapia delle dislipidemie e aferesi terapeutica, A.O. Universitaria Integrata di Verona, Verona, Italy), Alessandra **Romandini** (Unità Prevenzione Aterosclerosi, Centro Cardiologico Monzino, IRCCS, Milan, Italy), Elena **Sani** (U.O. Endocrinologia, Diabetologia e Malattie del Metabolismo, Centro regionale specializzato per la diagnosi e terapia delle dislipidemie e aferesi terapeutica, A.O. Universitaria Integrata di Verona, Verona, Italy), Silvia **Sarnari** (Clinica Medica e Geriatrica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche e IRCCS-INRCA, Ancona, Italy), Riccardo **Sarzano** (Clinica Medica e Geriatrica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche e IRCCS-INRCA, Ancona, Italy), Francesco **Sbrana** (Lipoapheresis Unit - Reference Center For Diagnosis And Treatment Of Inherited Dyslipidemias - Fondazione Toscana Gabriele Monasterio - Pisa, Italy), Roberto **Scicali** (Department of Clinical and Experimental Medicine, University of Catania, Ospedale Garibaldi, Catania, Italy), Michele **Scuruchi** (Department of Clinical and Experimental Medicine - Lipid Center - University Hospital G. Martino, Messina, Italy), Patrizia **Suppressa** (U.O. di Medicina Interna e Geriatria "C. Frugoni" e Centro di Assistenza e Ricerca Malattie Rare, A.O. Universitaria Policlinico Consortziale, Università degli Studi di Bari "Aldo Moro", Bari, Italy), Patrizia **Tarugi** (Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy), Chiara **Trenti** (Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy), Pierandrea **Vinci** (S.S. Malattie del Metabolismo, U.C.O. Clinica Medica, ASUGI, Università di Trieste, Trieste, Italy), José Pablo **Werba** (Unità

Prevenzione Aterosclerosi, Centro Cardiologico Monzino, IRCCS, Milan, Italy), Sabina **Zambon** (Dipartimento di Medicina, Università di Padova, Padua, Italy), Alberto **Zambon** (Dipartimento di Medicina, Università di Padova, Padua, Italy), Maria Grazia **Zenti** (Servizio di Diabetologia e Malattie Metaboliche "Ospedale P. Pederzoli" - Casa di Cura Privata S.p. A., Peschiera del Garda, Italy).

## References

- [1] B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, et al., Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, *Eur. Heart J.* 34 (45) (2013), <https://doi.org/10.1093/eurheartj/ehz273>, 3478–90a.
- [2] M. Putema, A. Taylor-Beadling, M. Williams, et al., Genetic testing for familial hypercholesterolemia—past, present, and future, *J. Lipid Res.* 62 (2021), 100139, <https://doi.org/10.1016/j.jlr.2021.100139> [published Online First: 2021/10/20].
- [3] J.C. Defesche, S.S. Gidding, M. Harada-Shiba, et al., Familial hypercholesterolaemia, *Nat. Rev. Dis. Prim.* 3 (2017), 17093, <https://doi.org/10.1038/nrdp.2017.93>.
- [4] A.L. Peterson, C.J. McNeal, D.P. Wilson, Prevention of atherosclerotic cardiovascular disease in children with familial hypercholesterolemia, *Curr. Atherosclerosis Rep.* 23 (10) (2021) 64, <https://doi.org/10.1007/s11883-021-00959-8> [published Online First: 2021/08/29].
- [5] S. Singh, V. Bittner, Familial hypercholesterolemia—epidemiology, diagnosis, and screening, *Curr. Atherosclerosis Rep.* 17 (2) (2015) 482, <https://doi.org/10.1007/s11883-014-0482-5>.
- [6] F. Mach, C. Baigent, A.L. Catapano, et al., ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, 2020, *Eur. Heart J.* 41 (1) (2019) 111–188, <https://doi.org/10.1093/eurheartj/ehz455> [published Online First: 2019/09/11].
- [7] Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group, *BMJ* 303 (6807) (1991) 893–896.
- [8] A. Boccatonda, I. Rossi, D. D'Ardes, et al., Comparison between different diagnostic scores for the diagnosis of familial hypercholesterolemia: assessment of their diagnostic accuracy in comparison with genetic testing, *Eur. Heart J.* 41 (Supplement 2) (2020), <https://doi.org/10.1093/ehjci/ehaa946.3206>.
- [9] K. Al-Rasadi, K. Al-Waili, H.A. Al-Sabti, et al., Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani arab population, *Oman Med. J.* 29 (2) (2014) 85–91, <https://doi.org/10.5001/omj.2014.22> [published Online First: 2014/04/10].
- [10] M.P. McGowan, S.H. Hosseini Dehkordi, P.M. Moriarty, et al., Diagnosis and treatment of heterozygous familial hypercholesterolemia, *J. Am. Heart Assoc.* 8 (24) (2019), e013225, <https://doi.org/10.1161/JAHA.119.013225> [published Online First: 2019/12/17].
- [11] F. Martino, F. Barilla, E. Martino, et al., Familial hypercholesterolaemia in children and adolescents: current and future perspective, *Curr. Pediatr. Rev.* (2022), <https://doi.org/10.2174/1573396318666220921155314> [published Online First: 2022/09/27].
- [12] C. Pederiva, M.E. Capra, C. Viggiano, et al., Early prevention of atherosclerosis: detection and management of hypercholesterolaemia in children and adolescents, *Life* 11 (4) (2021), <https://doi.org/10.3390/life11040345> [published Online First: 2021/05/01].
- [13] M. Gazzotti, M. Casula, S. Bertolini, et al., The role of registers in increasing knowledge and improving management of children and adolescents affected by familial hypercholesterolemia: the LIPIGEN pediatric group, *Front. Genet.* 13 (2022), 912510, <https://doi.org/10.3389/fgene.2022.912510> [published Online First: 2022/07/08].
- [14] M.A. Eissa, N.L. Mihalopoulos, R. Holubkov, et al., Changes in fasting lipids during puberty, *J. Pediatr.* 170 (2016) 199–205, <https://doi.org/10.1016/j.jpeds.2015.11.018> [published Online First: 2015/12/27].
- [15] J. Versmissen, D.M. Oosterveer, M. Yazdanpanah, et al., Efficacy of statins in familial hypercholesterolaemia: a long term cohort study, *BMJ* 337 (2008) a2423, <https://doi.org/10.1136/bmj.a2423> [published Online First: 2008/11/13].
- [16] M. Casula, E. Olmastroni, A. Pirillo, et al., Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: the LIPIGEN study, *Atherosclerosis* 277 (2018) 413–418, <https://doi.org/10.1016/j.atherosclerosis.2018.08.013>.
- [17] M. Gazzotti, M. Casula, E. Olmastroni, et al., How registers could enhance knowledge and characterization of genetic dyslipidaemias: the experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia, *Atherosclerosis Suppl.* 42 (2020) e35–e40, <https://doi.org/10.1016/j.atherosclerosis.2021.01.007>.
- [18] M. Averna, A.B. Cefalu, M. Casula, et al., Familial hypercholesterolemia: the Italian atherosclerosis society network (LIPIGEN), *Atherosclerosis Suppl.* 29 (2017) 11–16, <https://doi.org/10.1016/j.atherosclerosis.2017.07.001>.
- [19] J.R. Chora, M.A. Iacocca, L. Tichy, et al., The clinical genome resource (ClinGen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification, *Genet. Med. : official journal of the American College of Medical Genetics* 24 (2) (2022) 293–306, <https://doi.org/10.1016/j.gim.2021.09.012> [published Online First: 2021/12/16].
- [20] A.M. Medeiros, A.C. Alves, P. Aguiar, et al., Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia, *J. Lipid Res.* 55 (5) (2014) 947–955, <https://doi.org/10.1194/jlr.P043182> [published Online First: 2014/03/15].
- [21] S.S. Gidding, A. Wiegman, U. Groselj, et al., Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations, *European journal of preventive cardiology* 29 (18) (2022) 2301–2311, <https://doi.org/10.1093/eurjpc/zwac200> [published Online First: 2022/09/06].
- [22] J.M. Galema-Boers, J. Versmissen, H.W. Roeters van Lennep, et al., Cascade screening of familial hypercholesterolemia must go on, *Atherosclerosis* 242 (2) (2015) 415–417, <https://doi.org/10.1016/j.atherosclerosis.2015.07.020> [published Online First: 2015/08/19].
- [23] N. Qureshi, M.L.R. Da Silva, H. Abdul-Hamid, et al., Strategies for screening for familial hypercholesterolaemia in primary care and other community settings, *Cochrane Database Syst. Rev.* 10 (10) (2021), CD012985, <https://doi.org/10.1002/14651858.CD012985.pub2> [published Online First: 2021/10/08].
- [24] J. Albuquerque, A.M. Medeiros, A.C. Alves, et al., Performance comparison of different classification algorithms applied to the diagnosis of familial hypercholesterolemia in paediatric subjects, *Sci. Rep.* 12 (1) (2022) 1164, <https://doi.org/10.1038/s41598-022-05063-8> [published Online First: 2022/01/23].
- [25] S.E. Humphries, R.A. Whittall, C.S. Hubbart, et al., Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk, *J. Med. Genet.* 43 (12) (2006) 943–949, <https://doi.org/10.1136/jmg.2006.038356> [published Online First: 2006/12/05].
- [26] E. Olmastroni, M. Gazzotti, M. Arca, et al., Twelve variants polygenic score for low-density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with or without causative mutations, *J. Am. Heart Assoc.* 11 (7) (2022), e023668, <https://doi.org/10.1161/JAHA.121.023668> [published Online First: 2022/03/25].
- [27] C. Representatives of the Global Familial Hypercholesterolemia, K.A. Wilemon, J. Patel, et al., Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action, *JAMA cardiology* 5 (2) (2020) 217–229, <https://doi.org/10.1001/jamacardio.2019.5173> [published Online First: 2020/01/03].